Details for Patent: 9,499,493

Title:	2,4-pyrimidinediamine compounds and their uses
Abstract:	The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Inventor(s):	Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Payan; Donald G. (Hillsborough, CA), Molineaux; Susan (San Francisco, CA), Holland; Sacha J. (San Francisco, CA), Clough; Jeffrey (Redwood City, CA), Keim; Holger (Newbury Park, CA), Bhamidipati; Somasekhar (Foster City, CA), Sylvain; Catherine (San Mateo, CA), Li; Hui (Santa Clara, CA), Rossi; Alexander B. (Reedsport, OR)
Assignee:	Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Filing Date:	Sep 22, 2015
Application Number:	14/861,739
Claims:	1. A compound according to Formula (I) ##STR00063## or a salt thereof, wherein: one of R.sup.2 and R.sup.4 is a phenyl monosubstituted with --OH, --OR.sup.a, --O--C(O)OR.sup.a, --O--(CH.sub.2).sub.m--C(O)OR.sup.a, --O--(CH.sub.2).sub.m--NR.sup.cR.sup.c, --O--C(O)NR.sup.cR.sup.c, --O--(CH.sub.2).sub.m--C(O)NR.sup.cR.sup.c, --O--C(NH)NR.sup.cR.sup.c, --O--(CH.sub.2).sub.m--C(NH)NR.sup.cR.sup.c, --NH--(CH.sub.2).sub.m--NR.sup.cR.sup.c or --[NHC(O)]R.sup.d; the other of R.sup.2 and R.sup.4 is a phenyl monosubstituted or disubstituted with R.sup.8; R.sup.2 and R.sup.4 are different; R.sup.5 is fluoro, --CN, or (C1-C3) haloalkyl; each R.sup.8 is independently R.sup.a, R.sup.b, or R.sup.a substituted with one R.sup.a or R.sup.b; each R.sup.a is independently (C1-C6) alkyl, or 3-8 membered cycloheteroalkyl; each R.sup.b is independently --OH, --OR.sup.a, --NR.sup.cR.sup.c, halogen, --CF.sub.3, --CN, --NO.sub.2, --N.sub.3, --SO.sub.2NR.sup.cR.sup.c, --C(O)R.sup.a, --C(O)NR.sup.cR.sup.c, or --C(NH)NR.sup.cR.sup.c; each R.sup.c is independently H or R.sup.a; each R.sup.d is independently R.sup.a; and each m is independently an integer from 1 to 2. 2. The compound of claim 1, wherein R.sup.5 is (C1-C3) haloalkyl. 3. The compound of claim 1, wherein R.sup.5 is --CF.sub.3. 4. The compound of claim 2, wherein at least one R.sup.8 is R.sup.b and each R.sup.b is independently --OH, --OR.sup.a, --NR.sup.cR.sup.c, halogen, --CF.sub.3, --CN, --NO.sub.2, --N.sub.3, --SO.sub.2NR.sup.cR.sup.c, --C(O)R.sup.a, or --C(O)NR.sup.cR.sup.c. 5. The compound of claim 1, wherein R.sup.4 is a phenyl monosubstituted with OH, --OR.sup.a, --O--C(O)OR.sup.a, --O--(CH.sub.2).sub.m--C(O)OR.sup.a, --O--(CH.sub.2).sub.m--NR.sup.cR.sup.c, --O--C(O)NR.sup.cR.sup.c, --O--(CH.sub.2).sub.m--C(O)NR.sup.cR.sup.c, --O--C(NH)NR.sup.cR.sup.c, --O--(CH.sub.2).sub.m--C(NH)NR.sup.cR.sup.c, --NH--(CH.sub.2).sub.m--NR.sup.cR.sup.c or --[NHC(O)]R.sup.d. 6. The compound of claim 5, wherein R.sup.4 is a phenyl monosubstituted with --[NHC(O)]R.sup.d. 7. The compound of claim 6, wherein R.sup.d is (C1-C6)alkyl. 8. The compound of claim 1, wherein R.sup.2 is a phenyl disubstituted with R.sup.8. 9. The compound of claim 8, wherein at least one R.sup.8 is R.sup.a substituted with one R.sup.a or R.sup.b. 10. The compound of claim 9, wherein at least one R.sup.8 is a 3-8 membered cycloheteroalkyl substituted with one R.sup.a or R.sup.b. 11. The compound of claim 8, wherein at least one R.sup.8 is R.sup.b. 12. The compound of claim 8, wherein at least one R.sup.8 is OR.sup.a. 13. The compound of claim 12, wherein R.sup.a is (C1-C6)alkyl. 14. The compound of claim 8, wherein one R.sup.8 comprises piperazinyl. 15. The compound of claim 14, wherein the piperazinyl is substituted with one R.sup.a or R.sup.b. 16. A pharmaceutical composition, comprising the compound of claim 1 and a pharmaceutically acceptable excipient. 17. The compound of claim 1, wherein R.sup.4 is a phenyl monosubstituted with (C1-C6) alkyl.